m+Medelevator.RU
← Поиск публикаций
Journal of prosthodontics : official journal of the American College of Prosthodontists · 2018

Clinical Management Protocol for Dental Implants Inserted in Patients with Active Lichen Planus. Part II 4-Year Follow-Up.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Khamis Aya Khamis, Aboushelib Moustafa Nabil, Helal Mohamed Hamdy

Аннотация

PURPOSE: To evaluate marginal bone loss (MBL) of dental implants inserted in active lichen planus patients.

MATERIALS AND METHODS: The study included 59 subjects divided into 3 groups depending on their lichen planus diagnosis and administration of a low dose of corticosteroids: 17 healthy individuals, 20 controlled lichen planus patients controlled using low doses of systemic corticosteroids, and 22 noncontrolled lichen planus patients. During 4-year follow-up sessions MBL was evaluated, and biopsies were collected from lichen planus patients and examined. Two-way ANOVA was used to analyze the data (α = 0.05).

RESULTS: There was no statistically significant difference in MBL between healthy and controlled patients; however, noncontrolled patients exhibited increased MBL (F = 1309, p < 0.001) which reached 2.53 mm after 4 years. There were significant interactions between state of the disease (F = 1309, p < 0.001), evaluation time (F = 317, p < 0.001), and interaction between state of the disease and observation time (F = 159, p < 0.001). Histopathologic examination of collected biopsies revealed healthy tissue architecture of the controlled patients, while inflammatory cellular infiltration and signs of classical destructive tissue were observed for noncontrolled patients.

CONCLUSIONS: Lichen planus patients receiving dental implants should be controlled on a low-dose of corticosteroids to prevent accelerated MBL and to reduce remission of clinical manifestations.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты